Windtree Therapeutics Net Income From Continuing Ops Over Time
| WINT Stock | USD 0.02 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Windtree Therapeutics Performance and Windtree Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Windtree introduce new products? Factors like these will boost the valuation of Windtree Therapeutics. Anticipated expansion of Windtree directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Windtree Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Windtree Therapeutics requires distinguishing between market price and book value, where the latter reflects Windtree's accounting equity. The concept of intrinsic value—what Windtree Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Windtree Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Windtree Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Windtree Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Windtree Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Windtree Therapeutics and related stocks such as Revelation Biosciences, Dermata Therapeutics, and Avenue Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | 31.7 M | (12 M) | (12 M) | (10.8 M) | 875.1 K | (15 M) | (13.5 M) | (12.9 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.3 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| XRTX | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (3.8 M) | (629.6 K) | (1.3 M) | (1.7 M) | (7 M) | (2.2 M) | (3.3 M) | (3 M) | (3.1 M) |
| VRAX | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (672.9 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| AIMD | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (10 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| NCEL | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (22.7 M) | (12 M) | (26.6 M) | (30.5 M) | (32.1 M) |
| GTBP | (23.5 M) | (23.5 M) | (23.5 M) | (23.5 M) | (23.5 M) | (21.5 M) | 21 M | (143.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (10.2 M) | (13.2 M) | (15.1 M) | (15.9 M) |
| ELAB | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (1.8 M) | (4.3 M) | (4 M) | (3.6 M) | (3.8 M) |
Windtree Therapeutics and related stocks such as Revelation Biosciences, Dermata Therapeutics, and Avenue Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Windtree Therapeutics | WINT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2600 Kelly Road, |
| Exchange | NASDAQ Exchange |
USD 0.02
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.